Founder - Robert H. Schwartz, Ph.D.
Dr. Robert Schwartz is a 30-year veteran of the pharmaceutical industry with broad-based experience in drug development and commercialization. He began his career in 1979 as a research chemist at Ciba-Geigy Corporation (9 + years) and then joined E.R. Squibb & Sons in 1989 where he was responsible for coordinating the non-clinical development of the company’s pipeline assets. In July 1997, Robert joined Bristol-Myers Squibb’s (BMS’) U.S. Oncology business where he was responsible for new business ventures and life-cycle management. He transitioned to BMS’ Licensing and Business Development (later Strategic Transactions) group in 2002 where he was credited with rebuilding the company’s oncology pipeline. Dr. Schwartz is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.
Joshua M. Schwartz, ESQ
Mr. Schwartz received his B.A. from Rutgers College and then went on to study law at the Thomas M. Cooley Law School from which he graduated in 2008. Joshua has served as a Law Clerk in the Chambers of the Hon. William M. Skretny, Western District of New York (Buffalo, NY) and has gained experience in corporate law at the law offices of Shamy, Shipers & Lonski, P.C. (New Brunswick, NJ). Mr. Schwartz is a member of the New Jersey Bar and is General Counsel for RHS Advisors.
Each member of the RHS Advisors technical team has with more than 15 years experience in their respective functional areas
- Pre-/non-clinical development including efficacy, toxicology and DMPK studies, formulation development and API synthesis
- Clinical development including human pharmacology studies
- Biostatistics and data management
- CMC and clinical regulatory affairs